Skip to main content
SpringerLink
Log in

Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Cheah CY, Seymour JF, Wang ML (2016) Mantle cell lymphoma. J Clin Oncol 34(11):1256–1269

    Article  CAS  Google Scholar 

  2. Maddocks K (2018) Update on mantle cell lymphoma. Blood 132(16):1647–1656

    Article  CAS  Google Scholar 

  3. Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E, European Mantle Cell Lymphoma Network (2015) High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 126(5):604–611

    Article  CAS  Google Scholar 

  4. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW (2018) Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 378(13):1211–1223

    Article  CAS  Google Scholar 

  5. Jiang C, Zhang R, Zhang S et al (2019) Targeting PI3K and PLK1 to overcome ibrutinib-venetoclax resistance in mantle cell lymphoma. Blood 134(Supplement_1):4062–4062

    Article  Google Scholar 

  6. Jiang VC, Lian J, Huang S et al (2020) Oncogenic MALT1 promotes cell survival and mediates ibrutinib resistance and ibrutinib-venetoclax resistance in mantle cell lymphoma. Blood 136(Supplement 1):18–18

    Article  Google Scholar 

  7. Jiang VC, Zhang S, Lian J et al (2020) Single cell transcriptomic evolution and resistance mechanisms of BTK and BCL-2 inhibition in mantle cell lymphoma. Blood 136(Supplement 1):33–34

    Google Scholar 

  8. Jordan AA, McIntosh J, Liu Y et al (2020) Targeting antibody checkpoint Fcgriib using monoclonal antibody BI-1206 to overcome therapeutic resistance in mantle cell lymphoma. Blood 136(Supplement 1):35

    Article  Google Scholar 

  9. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA (2019) Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leukemia Lymphoma 60(11):2712–2719

    Article  CAS  Google Scholar 

  10. Mato AR, Sharman JP, Biondo J et al (2020) Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results. JCO 38(15_suppl):8028

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Univ Paris Est Creteil, INSERM, F-94010, Creteil, France

    Louise Roulin, Corinne Haioun & François Lemonnier

  2. lymphoid malignancies unit, APHP, Henri Mondor Hospital, 94010, Créteil, France

    Louise Roulin, Corinne Haioun & François Lemonnier

Authors
  1. Louise Roulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corinne Haioun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. François Lemonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louise Roulin.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

Corinne Haioun received honoraria from Roche, Janssen-Cilag, Gilead, Takeda, Miltenyi, and Servier. Francois Lemonnier and Louise Roulin declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roulin, L., Haioun, C. & Lemonnier, F. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma. Ann Hematol 100, 1345–1347 (2021). https://doi.org/10.1007/s00277-021-04469-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04469-0

Search

Navigation